The use of ribosomal crystal structures in antibiotic drug design

Current Opinion in Investigational Drugs

Volumn 10, Issue 8, 2009, Pages 750-765

  Wimberly, Brian T ^a  

^a Rib X Pharmaceuticals Incorporated   (United States)

Author keywords

Aminoglycoside; Antibacterial; Antibiotic; Linezolid; Oxazolidinone; Ribosome; SBDD; Structure based drug design

Indexed keywords

9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; AMADACYCLINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANISOMYCIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BLASTICIDIN S; CEM 101; CETHROMYCIN; CHLORAMPHENICOL; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; EDP 322; GIROLLINE; KETOLIDE; LINEZOLID; NOSIHEPTIDE; NXL 103; OXAZOLIDINONE DERIVATIVE; PTK 0796; PUROMYCIN DERIVATIVE; RADEZOLID; RESTANZA; SB 280080; SB 571519; STREPTOGRAMIN DERIVATIVE; THIOSTREPTON; TIAMULIN; TR 701; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRGINIAMYCIN M; VIRGINIAMYCIN S;

ANTIMICROBIAL ACTIVITY; BINDING KINETICS; BINDING SITE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG STRUCTURE; HUMAN; LIGAND BINDING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; RIBOSOME; RIBOSOME SUBUNIT; SKIN INFECTION; STRUCTURE ACTIVITY RELATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; RIBOSOMES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68649102987     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS et al: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J Am Med Assoc (2007) 298(15):1763-1771.
2. Brown SD, Farrell DJ: Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J Antimicrob Chemother (2004) 54 (Suppl 1):i23-i29.
3. Brown SD, Farrell DJ, Morrissey I: Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. J Clin Microbiol (2004) 42(11):4980-4987.
4. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP: Emergence and spread of Streptococcus pneumoniae with erm (B) and mef (A) resistance. Emerg Infect Dis (2005) 11(6):851- 858.
5. McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, Cieslak P, Samore MH et al: Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med (2003) 9(4):424-430.
6. Davis KA, Moran KA, McAllister CK, Gray PJ: Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis (2005) 11(8):1218-1224.
7. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL: Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2007) 6(1):29-40.
8. Franceschi F, Duffy EM: Structure-based drug design meets the ribosome. Biochem Pharmacol (2006) 71(7):1016-1025.
9. Sutcliffe JA: Improving on nature: Antibiotics that target the ribosome. Curr Opin Microbiol (2005) 8(5):534-542.
10. Knowles DJ, Foloppe N, Matassova NB, Murchie AI: The bacterial ribosome, a promising focus for structure-based drug design. Curr Opin Pharmacol (2002) 2(5):501-506.
11. Vázquez D: Inhibitors of Protein Biosynthesis. (1979) Springer Verlag, Berlin, Germany.
12. Wimberly BT, Brodersen DE, Clemons WM Jr, Morgan-Warren RJ, Carter AP, Vonrhein C, Hartsch T, Ramakrishnan V: Structure of the 30S ribosomal subunit. Nature (2000) 407 (6802):327-339.
13. Schluenzen F, Tocilj A, Zarivach R, Harms J, Gluehmann M, Janell D, Bashan A, Bartels H, Agmon I, Franceschi F, Yonath A: Structure of functionally activated small ribosomal subunit at 3.3 Angstroms resolution. Cell (2000) 102(5):615-623.
14. Ban N, Nissen P, Hansen J, Moore PB, Steitz TA: The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science (2000) 289 (5481):905-920.
15. Schmeing TM, Seila AC, Hansen JL, Freeborn B, Soukup JK, Scaringe SA, Strobel SA, Moore PB, Steitz TA: A pre-translocational intermediate in protein synthesis observed in crystals of enzymatically active 50S subunits. Nat Struct Biol (2002) 9(3):225-230.
16. Hansen JL, Ippolito JA, Ban N, Nissen P, Moore PB, Steitz TA: The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol Cell (2002) 10(1):117-128.
17. Schmeing TM, Huang KS, Kitchen DE, Strobel SA, Steitz TA: Structural insights into the roles of water and the 2' hydroxyl of the P site tRNA in the peptidyl transferase reaction. Mol Cell (2005) 20(3):437-448.
18. Schmeing TM, Moore PB, Steitz TA: Structures of deacylated tRNA mimics bound to the E site of the large ribosomal subunit. RNA (2003) 9(11):1345-1352.
19. Harms J, Schluenzen F, Zarivach R, Bashan A, Gat S, Agmon I, Bartels H, Franceschi F, Yonath A: High resolution structure of the large ribosomal subunit from a mesophilic eubacterium. Cell (2001) 107(5):679-688.
20. Rib-X Pharmaceuticals Inc: Rib-X Pharmaceuticals Inc granted key antibiotic drug discovery patents - Company also announces first ever Gram-positive 50S ribosome structure. Press Release (2005): October 5. www.rib-x.com/news-and-events/release-2005-10-05
21. Yusupov MM, Yusupova GZ, Baucom A, Lieberman K, Earnest TN, Cate JH, Noller HF: Crystal structure of the ribosome at 5.5 A resolution. Science (2001) 292 (5518):883-896.
22. Schuwirth BS, Borovinskaya MA, Hau CW, Zhang W, Vila-Sanjurjo A, Holton JM, Cate JH: Structures of the bacterial ribosome at 3.5 A resolution. Science (2005) 310 (5749):827-834.
23. Selmer M, Dunham CM, Murphy FV 4th, Weixlbaumer A, Petry S, Kelley AC, Weir JR, Ramakrishnan V: Structure of the 70S ribosome complexed with mRNA and tRNA. Science (2006) 313 (5795):1935-1942.
24. Rib-X Pharmaceuticals Inc: Rib-X Pharmaceuticals Inc and the Medical Research Council announce key collaboration. Press Release (2007): April 25. www.rib-x.com/news-and-events/release-2007-04-25
25. Pharmacia Corporation: New antibiotic addresses challenge of treating gram-positive bacterial infections and may help patients leave hospital sooner. Press Release (2000): May 29.
26. Wilcox MH: Update on linezolid: The first oxazolidinone antibiotic. Expert Opin Pharmacother (2005) 6(13):2315-2326.
27. Bozdogan B, Appelbaum PC: Oxazolidinones: Activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents (2004) 23(2):113-119.
28. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358 (9277):207-208.
29. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, Bamford K, Ayles H, Johnson AP: Linezolid-resistant enterococci: Report of the first isolates in the United Kingdom. J Antimicrob Chemother (2002) 50(5):743-746.
30. Ippolito JA, Kanyo ZF, Wang D, Franceschi FJ, Moore PB, Steitz TA, Duffy EM: Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem (2008) 51(12):3353-3356. The crystal structure of linezolid bound to the 50S ribosomal subunit in the presence of a P-site substrate analog provides a high-resolution view of this drug bound to the 50S A site.
31. Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P: The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA (2008) 105(36):13339-13344. • A lower-resolution crystal structure of linezolid bound to the 50S ribosomal subunit in the absence of substrate analogs.
32. Matassova NB, Rodnina MV, Endermann R, Kroll HP, Pleiss U, Wild H, Wintermeyer W: Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA (1999) 5(7):939-946.
33. Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF, Buysse JM: Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother (1997) 41(10):2132-2136.
34. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother (1998) 42(12):3251-3255.
35. Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS: The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell (2007) 26(3): 393-402. • A series of photoreactive oxazolidinones were cross-linked inside living cells to ribosomal RNA and to the factor LepA. The results suggested a low-resolution model for oxazolidinone binding to the PTC that is consistent with high-resolution crystal structures.
36. Kloss P, Xiong L, Shinabarger DL, Mankin AS: Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol (1999) 294(1):93-101.
37. Xiong L, Kloss P, Douthwaite S, Andersen NM, Swaney S, Shinabarger DL, Mankin AS: Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol (2000) 182(19):5325- 5331.
38. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, Noskin GA: Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant Enterococci. Antimicrob Agents Chemother (2001) 45(7):2154-2156.
39. Blaha G, Gürel G, Schroeder SJ, Moore PB, Steitz TA: Mutations outside the anisomycin-binding site can make ribosomes drug-resistant. J Mol Biol (2008) 379(3):505-519.
40. Zhou J, Bhattacharjee A, Chen S, Chen Y, Duffy E, Farmer J, Goldberg J, Hanselmann R, Ippolito JA, Lou R, Orbin A et al: Design at the atomic level: Design of biaryloxazolidinones as potent orally active antibiotics. Bioorg Med Chem Lett (2008) 18(23):6175-6178. • Structure-based development of a promising biaryl oxazolidinone lead into a novel series of designer oxazolidinones with enhanced potency, spectrum and bioavailability.
41. Zhou J, Bhattacharjee A, Chen S, Chen Y, Duffy E, Farmer J, Goldberg J, Hanselmann R, Ippolito JA, Lou R, Orbin A et al: Design at the atomic level: Generation of novel hybrid biaryloxazolidinones as promising new antibiotics. Bioorg Med Chem Lett (2008) 18(23):6179-6183. • Structure-based discovery of a biaryl oxazolidinone scaffold as a promising lead for designer oxazolidinones.
42. Hansen JL, Moore PB, Steitz TA: Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J Mol Biol (2003) 330(5):1061-1075.
43. Jorgensen WL: The many roles of computation in drug discovery. Science (2004) 303 (5665):1813-1818.
44. Wang D, Sherer E, Duffy E: A computational suite for the discovery of designer oxazolidinones suitable for intravenous and oral usage. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (2005).
45. Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J: In vitro activities of the RX-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother (2008) 52(5):1653-1662.
46. File T Jr, Bagheri F, Bush L, Desanto J, Markowitz A, Merrick B, Pullman J, Topkis R, Burak E, Hopkins S: A phase 2 study comparing two doses of radezolid to linezolid in adults with uncomplicated skin and skin structure infections (uSSSI). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (2008).
47. Ogle JM, Murphy FV, Tarry MJ, Ramakrishnan V: Selection of tRNA by the ribosome requires a transition from an open to a closed form. Cell (2002) 111(5):721-732.
48. Pfister P, Hobbie S, Vicens Q, Böttger EC, Westhof E: The molecular basis for A-site mutations conferring aminoglycoside resistance: Relationship between ribosomal susceptibility and X-ray crystal structures. Chembiochem (2003) 4(10):1078-1088.
49. Vicens Q, Westhof E: Molecular recognition of aminoglycoside antibiotics by ribosomal RNA and resistance enzymes: An analysis of X-ray crystal structures. Biopolymers (2003) 70(1): 42-57.
50. Tor Y: The ribosomal A-site as an inspiration for the design of RNA binders. Biochimie (2006) 88(8):1045-1051.
51. Hainrichson M, Nudelman I, Baasov T: Designer aminoglycosides: The race to develop improved antibiotics and compounds for the treatment of human genetic diseases. Org Biomol Chem (2008) 6(2):227-239.
52. Zhou Y, Gregor VE, Sun Z, Ayida BK, Winters GC, Murphy D, Simonsen KB, Vourloumis D, Fish S, Froelich JM, Wall D: Structureguided discovery of novel aminoglycoside mimetics as antibacterial translation inhibitors. Antimicrob Agents Chemother (2005) 49(12):4942-4949. • Structure-guided discovery and characterization of a novel 3, 5-diaminopiperidinyl triazine scaffold that targets the 30S A site.
53. Foloppe N, Chen IJ, Davis B, Hold A, Morley D, Howes R: A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site. Bioorg Med Chem (2004) 12(5):935-947.
54. Arbeit RD, Roberts JA, Forsythe AR, Johnston SM, Seyedi F, Pukshansky M, Tanaka SK: Safety and efficacy of PTK 0796: Results of the phase 2 study in complicated skin and skin structure infections following iv and oral step-down therapy. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA (2008).
55. Im W, Choi S, Rhee J: Structure-activity relationship of substituted pyridyl phenyl oxazolidinone derivatives, including TR-700 (DA-7157). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2007).
56. Bien P, Prokocimer P, Munoz KA, Bohn J: The safety of 21-day multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland (2009).
57. Advanced Life Sciences Inc: Advanced Life Sciences announces supplemental efficacy data from first pivotal phase 3 pneumonia clinical trial. Press Release (2007): July 02.
58. Wang G, Qiu Y, Niu D, Vo NH, Beach T, Polemeropoulos A, Scorneaux B, Arya A, Schluenzen F, Harms JM, Albrecht R et al: Design, synthesis and antibacterial activities of novel 6, 11 3-carbon-bridged ketolides. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2003).
59. Enanta Pharmaceuticals Inc: Enanta initiates phase 1 study on EDP-322, an oral antibiotic with activity against hospital-and community-acquired MRSA. Press Release (2008): September 15. www.enanta.com/pr-091508. html
60. Cempra Inc: Cempra Pharmaceuticals and Biovista enter agreement for macrolide clinical trial design support studies. Press Release (2008): September 30. cempra.com/news/press/archive/09302008.asp
61. Still JG, Clark K, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ: Single oral dose pharmacokinetics and safety of CEM-101 in healthy subjects. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2008).
62. Llano-Sotelo B, Klepacki D, Vazquez-Laslop N, Mankin AS: Binding and action of CEM-101, a new macrolide/ketolide in development for treating infections with macrolide-resistant and macrolide-susceptible bacteria. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (2008).
63. Novexel Corporation: Novexel reports positive phase II trial results with NXL102 in adult patients with community-acquired pneumonia. Press Release (2008): October 23. www.novexel.com/includes/cms/-contenus/mod- press-releases/CP-2310-2008.pdf
64. Nissen P, Hansen J, Ban N, Moore PB, Steitz TA: The structural basis of ribosome activity in peptide bond synthesis. Science (2000) 289 (5481):920-930.
65. Schlünzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature (2001) 413 (6858):814-821.
66. Tu D, Blaha G, Moore PB, Steitz TA: Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell (2005) 121(2):257-270.
67. Harms JM, Schlünzen F, Fucini P, Bartels H, Yonath A: Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol (2004) 2:4.
68. Schlünzen F, Pyetan E, Fucini P, Yonath A, Harms JM: Inhibition of peptide bond formation by pleuromutilins: The structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol (2004) 54(5):1287-1294.
69. Davidovich C, Bashan A, Auerbach-Nevo T, Yaggie RD, Gontarek RR, Yonath A: Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc Natl Acad Sci USA (2007) 104(11):4291-4296.
70. Schroeder SJ, Blaha G, Tirado-Rives J, Steitz TA, Moore PB: The structures of antibiotics bound to the E site region of the 50 S ribosomal subunit of Haloarcula marismortui: 13-Deoxytedanolide and girodazole. J Mol Biol (2007) 367(5):1471-1479. • Crystal structures of two distinct classes of eukaryotic-specific antibiotics bound to the 50S ribosomal subunit.
71. Harms JM, Wilson DN, Schluenzen F, Connell SR, Stachelhaus T, Zaborowska Z, Spahn CM, Fucini P: Translational regulation via L11: Molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol Cell (2008) 30(1):26-38. • Crystal structures of several members of the thiostrepton family of antibiotics bound to the factor-binding site of the 50S ribosomal subunit.
72. Schlünzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure (2003) 11(3):329-338.
73. Berisio R, Schluenzen F, Harms J, Bashan A, Auerbach T, Baram D, Yonath A: Structural insight into the role of the ribosomal tunnel in cellular regulation. Nat Struct Biol (2003) 10(5):366-370.
74. Wilson DN, Harms JM, Nierhaus KH, Schlünzen F, Fucini P: Species-specific antibiotic-ribosome interactions: Implications for drug development. Biol Chem (2005) 386(12):1239-1252.
75. Berisio R, Harms J, Schluenzen F, Zarivach R, Hansen HA, Fucini P, Yonath A: Structural insight into the antibiotic action of telithromycin against resistant mutants. J Bacteriol (2003) 185(14):4276-4279.
76. Qiu T, Jian T, Vo NH, Hou Y, Chen Z, Haley T, Polemeropoulos A, Schluenzen F, Harms JM, Albrecht R, Yonath A et al: Novel 4'-O-substituted tylosin derivatives to overcome bacterial resistance. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2003).
77. Borovinskaya MA, Pai RD, Zhang W, Schuwirth BS, Holton JM, Hirokawa G, Kaji H, Kaji A, Cate JH: Structural basis for aminoglycoside inhibition of bacterial ribosome recycling. Nat Struct Mol Biol (2007) 14(8):727-732.
78. Schroeder SJ, Blaha G, Moore PB: Negamycin binds to the wall of the nascent chain exit tunnel of the 50S ribosomal subunit. Antimicrob Agents Chemother (2007) 51(12):4462-4465.
79. Vicens Q, Westhof E: Crystal structure of a complex between the aminoglycoside tobramycin and an oligonucleotide containing the ribosomal decoding a site. Chem Biol (2002) 9(6):747-755.
80. Vicens Q, Westhof E: Crystal structure of geneticin bound to a bacterial 16S ribosomal RNA A site oligonucleotide. J Mol Biol (2003) 326(4):1175-1188.
81. Han Q, Zhao Q, Fish S, Simonsen KB, Vourloumis D, Froelich JM, Wall D, Hermann T: Molecular recognition by glycoside pseudo base pairs and triples in an apramycin-RNA complex. Angew Chem Int Ed Engl (2005) 44(18):2694-2700.
82. Kondo J, François B, Urzhumtsev A, Westhof E: Crystal structure of the Homo sapiens cytoplasmic ribosomal decoding site complexed with apramycin. Angew Chem Int Ed Engl (2006) 45(20):3310-3314.
83. Hermann T, Tereshko V, Skripkin E, Patel DJ: Apramycin recognition by the human ribosomal decoding site. Blood Cells Mol Dis (2007) 38(3):193-198.
84. Vicens Q, Westhof E: Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure (2001) 9(8):647-658.
85. Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature (2000) 407 (6802):340-348.
86. Ogle JM, Brodersen DE, Clemons WM Jr, Tarry MJ, Carter AP, Ramakrishnan V: Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science (2001) 292 (5518):897-902.
87. Lynch SR, Puglisi JD: Structural origins of aminoglycoside specificity for prokaryotic ribosomes. J Mol Biol (2001) 306(5):1037- 1058.
88. Fourmy D, Yoshizawa S, Puglisi JD: Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. J Mol Biol (1998) 277(2):333-345.
89. Kondo J, Hainrichson M, Nudelman I, Shallom-Shezifi D, Barbieri CM, Pilch DS, Westhof E, Baasov T: Differential selectivity of natural and synthetic aminoglycosides towards the eukaryotic and prokaryotic decoding A sites. Chembiochem (2007) 8(14):1700-1709.
90. François B, Russell RJ, Murray JB, Aboul-ela F, Masquida B, Vicens Q, Westhof E: Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: Role of the number of rings and positive charges in the specific binding leading to miscoding. Nucleic Acids Res (2005) 33(17):5677-5690.
91. Yoshizawa S, Fourmy D, Puglisi JD: Structural origins of gentamicin antibiotic action. EMBO J (1998) 17(22):6437-6448.
92. Zhao F, Zhao Q, Blount KF, Han Q, Tor Y, Hermann T: Molecular recognition of RNA by neomycin and a restricted neomycin derivative. Angew Chem Int Ed Engl (2005) 44(33):5329-5334.
93. Kondo J, François B, Russell RJ, Murray JB, Westhof E: Crystal structure of the bacterial ribosomal decoding site complexed with amikacin containing the γ-amino-α-hydroxybutyryl (haba) group. Biochimie (2006) 88(8):1027-1031.
94. Russell RJ, Murray JB, Lentzen G, Haddad J, Mobashery S: The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography J Am Chem Soc (2003) 125(12):3410-3411.
95. François B, Szychowski J, Adhikari SS, Pachamuthu K, Swayze EE, Griffey RH, Migawa MT, Westhof E, Hanessian S: Antibacterial aminoglycosides with a modified mode of binding to the ribosomal-RNA decoding site. Angew Chem Int Ed Engl (2004) 43(48):6735-6738.
96. Kondo J, Pachamuthu K, François B, Szychowski J, Hanessian S, Westhof E: Crystal structure of the bacterial ribosomal decoding site complexed with a synthetic doubly functionalized paromomycin derivative: A new specific binding mode to an a-minor motif enhances in vitro antibacterial activity. ChemMedChem (2007) 2(11):1631-1638.
97. Brodersen DE, Clemons WM Jr, Carter AP, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell (2000) 103(7):1143-1154.
98. Borovinskaya MA, Shoji S, Fredrick K, Cate JH: Structural basis for hygromycin B inhibition of protein biosynthesis. RNA (2008) 14(8):1590-1599.
99. Pioletti M, Schlünzen F, Harms J, Zarivach R, Glühmann M, Avila H, Bashan A, Bartels H, Auerbach T, Jacobi C, Hartsch T et al: Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J (2001) 20(8):1829-1839.
100. Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA: Functional, biophysical and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother (2006) 50(6):2156- 2166.
101. Borovinskaya MA, Shoji S, Holton JM, Fredrick K, Cate JH: A steric block in translation caused by the antibiotic spectinomycin. ACS Chem Biol (2007) 2(8):545-552.
102. Schluenzen F, Takemoto C, Wilson DN, Kaminishi T, Harms JM, Hanawa-Suetsugu K, Szaflarski W, Kawazoe M, Shirouzu M, Nierhaus KH, Yokoyama S et al: The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nat Struct Mol Biol (2006) 13(10):871-878.
103. Schuwirth BS, Day JM, Hau CW, Janssen GR, Dahlberg AE, Cate JH, Vila-Sanjurjo A: Structural analysis of kasugamycin inhibition of translation. Nat Struct Mol Biol (2006) 13(10):879-886.